Home
/
NEKTAR THERAPEUTICS
/
Financials
/
Quarterly
NEKTAR THERAPEUTICS — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that NEKTAR THERAPEUTICS filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$38.02M
May 10, 2018
Q3
2017
Sep 30, 2017
$152.93M
Nov 8, 2017
Q2
2017
Jun 30, 2017
$34.59M
Aug 9, 2017
Q1
2018
Mar 31, 2017
$24.73M
May 10, 2018
Q3
2017
Sep 30, 2016
$36.34M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$32.77M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$58.88M
May 10, 2017
Q3
2016
Sep 30, 2015
$59.95M
Nov 4, 2016
Q2
2016
Jun 30, 2015
$22.66M
Aug 4, 2016
Q1
2016
Mar 31, 2015
$108.80M
May 4, 2016
Q3
2015
Sep 30, 2014
$132.87M
Nov 6, 2015
Q2
2015
Jun 30, 2014
$28.51M
Aug 6, 2015
Q1
2015
Mar 31, 2014
$19.77M
May 1, 2015
Q3
2014
Sep 30, 2013
$60.91M
Nov 7, 2014
Q2
2014
Jun 30, 2013
$33.86M
Aug 1, 2014
Q1
2014
Mar 31, 2013
$23.00M
May 8, 2014
Q3
2013
Sep 30, 2012
$18.41M
Nov 7, 2013
Q2
2013
Jun 30, 2012
$23.68M
Aug 9, 2013
Q1
2013
Mar 31, 2012
$17.95M
May 9, 2013
Q3
2012
Sep 30, 2011
$27.07M
Nov 9, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$11.79M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$11.18M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$10.46M
May 9, 2025
Q3
2025
Sep 30, 2024
$24.12M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$23.49M
Aug 8, 2025
Q1
2025
Mar 31, 2024
$21.64M
May 9, 2025
Q3
2024
Sep 30, 2023
$24.14M
Nov 8, 2024
Q2
2024
Jun 30, 2023
$20.50M
Aug 9, 2024
Q1
2024
Mar 31, 2023
$21.59M
May 10, 2024
Q3
2023
Sep 30, 2022
$23.63M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$21.59M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$24.82M
May 10, 2023
Q3
2022
Sep 30, 2021
$24.92M
Nov 4, 2022
Q2
2022
Jun 30, 2021
$28.33M
Aug 5, 2022
Q1
2022
Mar 31, 2021
$23.65M
May 6, 2022
Q3
2021
Sep 30, 2020
$30.03M
Nov 5, 2021
Q2
2021
Jun 30, 2020
$48.85M
Aug 6, 2021
Q1
2021
Mar 31, 2020
$50.57M
May 7, 2021
Q3
2020
Sep 30, 2019
$29.22M
Nov 6, 2020
Q2
2020
Jun 30, 2019
$23.32M
Aug 7, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($35.52M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($41.59M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($50.88M)
May 9, 2025
Q3
2025
Sep 30, 2024
($37.06M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($52.36M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($36.80M)
May 9, 2025
Q3
2024
Sep 30, 2023
($45.84M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
($51.12M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($137.02M)
May 10, 2024
Q3
2023
Sep 30, 2022
($59.05M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($159.07M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($90.39M)
May 10, 2023
Q3
2022
Sep 30, 2021
($129.71M)
Nov 4, 2022
Q2
2022
Jun 30, 2021
($125.52M)
Aug 5, 2022
Q1
2022
Mar 31, 2021
($122.97M)
May 6, 2022
Q3
2021
Sep 30, 2020
($108.59M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($80.00M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($138.65M)
May 7, 2021
Q3
2020
Sep 30, 2019
($98.59M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($110.29M)
Aug 7, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($31.67M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($36.23M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($44.54M)
May 9, 2025
Q3
2025
Sep 30, 2024
($34.35M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($49.77M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($35.43M)
May 9, 2025
Q3
2024
Sep 30, 2023
($44.86M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
($50.60M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($134.71M)
May 10, 2024
Q3
2023
Sep 30, 2022
($54.30M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($152.84M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($116.56M)
May 10, 2023
Q3
2022
Sep 30, 2021
($113.60M)
Nov 4, 2022
Q2
2022
Jun 30, 2021
($110.21M)
Aug 5, 2022
Q1
2022
Mar 31, 2021
($109.39M)
May 6, 2022
Q3
2021
Sep 30, 2020
($103.05M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($77.71M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($133.63M)
May 7, 2021
Q3
2020
Sep 30, 2019
($98.74M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($110.97M)
Aug 7, 2020